H.C. Wainwright Starts Inotek Pharmaceuticals (ITEK) at Buy

September 20, 2016 8:34 AM EDT
Get Alerts ITEK Hot Sheet
Price: $1.65 --0%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 13 | New: 9
Trade ITEK Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

H.C. Wainwright initiated coverage on Inotek Pharmaceuticals (NASDAQ: ITEK) with a Buy rating and a price target of $22. Analyst Corey Davis is bullish on its lead drug, trabodenoson.

"Our investment thesis hinges on the success of trabodenoson (and its second product,trabodenoson in combination with latanoprost, FDC), for glaucoma. Inotek has successfully completed Phase 2 (one in 2012; the secondin 2015), it started the Phase 3 MATrX-1 monotherapy trial in September 2015, and started the Phase 2 combination study in July 2016. The first big data release should come from MATrX-1 in late2016—what we see as the primary near-term stock driver," said Davis.

For an analyst ratings summary and ratings history on Inotek Pharmaceuticals click here. For more ratings news on Inotek Pharmaceuticals click here.

Shares of Inotek Pharmaceuticals closed at $8.47 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment